Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin’s Lymphoma: A Single-Center Cohort Study
It has been suggested that the effect of coronavirus disease 2019 (COVID-19) booster vaccination in patients with B-cell non-Hodgkin’s lymphoma (B-NHL) is inferior to that in healthy individuals. However, differences according to histological subtype or treatment status are unclear. In addition, the...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/16/3/328 |
| _version_ | 1797239126345383936 |
|---|---|
| author | Makoto Saito Akio Mori Takashi Ishio Mirei Kobayashi Shihori Tsukamoto Sayaka Kajikawa Emi Yokoyama Minoru Kanaya Koh Izumiyama Haruna Muraki Masanobu Morioka Takeshi Kondo |
| author_facet | Makoto Saito Akio Mori Takashi Ishio Mirei Kobayashi Shihori Tsukamoto Sayaka Kajikawa Emi Yokoyama Minoru Kanaya Koh Izumiyama Haruna Muraki Masanobu Morioka Takeshi Kondo |
| author_sort | Makoto Saito |
| collection | DOAJ |
| description | It has been suggested that the effect of coronavirus disease 2019 (COVID-19) booster vaccination in patients with B-cell non-Hodgkin’s lymphoma (B-NHL) is inferior to that in healthy individuals. However, differences according to histological subtype or treatment status are unclear. In addition, there has been less research on patients who subsequently develop breakthrough infections. We investigated the effects of the first COVID-19 booster vaccination for patients with B-NHL and the clinical features of breakthrough infections in the Omicron variant era. In this study, B-NHL was classified into two histological subtypes: aggressive lymphoma and indolent lymphoma. Next, patients were subdivided according to treatment with anticancer drugs at the start of the first vaccination. We also examined the clinical characteristics and outcomes of patients who had breakthrough infections after a booster vaccination. The booster effect of the COVID-19 mRNA vaccine in patients with B-NHL varied considerably depending on treatment status at the initial vaccination. In the patient group at more than 1 year after the last anticancer drug treatment, regardless of the histological subtype, the booster effect was comparable to that in the healthy control group. In contrast, the booster effect was significantly poorer in the other patient groups. However, of the 213 patients who received the booster vaccine, 22 patients (10.3%) were infected with COVID-19, and 18 patients (81.8%) had mild disease; these cases included the patients who remained seronegative. Thus, we believe that booster vaccinations may help in reducing the severity of Omicron variant COVID-19 infection in patients with B-NHL. |
| first_indexed | 2024-04-24T17:46:35Z |
| format | Article |
| id | doaj.art-d15c1e4b459c43a998d367c1565332c5 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-04-24T17:46:35Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-d15c1e4b459c43a998d367c1565332c52024-03-27T14:07:34ZengMDPI AGViruses1999-49152024-02-0116332810.3390/v16030328Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin’s Lymphoma: A Single-Center Cohort StudyMakoto Saito0Akio Mori1Takashi Ishio2Mirei Kobayashi3Shihori Tsukamoto4Sayaka Kajikawa5Emi Yokoyama6Minoru Kanaya7Koh Izumiyama8Haruna Muraki9Masanobu Morioka10Takeshi Kondo11Blood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, JapanBlood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, JapanBlood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, JapanBlood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, JapanBlood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, JapanBlood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, JapanBlood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, JapanBlood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, JapanBlood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, JapanDivision of Laboratory, Aiiku Hospital, Sapporo 064-0804, Hokkaido, JapanBlood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, JapanBlood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, JapanIt has been suggested that the effect of coronavirus disease 2019 (COVID-19) booster vaccination in patients with B-cell non-Hodgkin’s lymphoma (B-NHL) is inferior to that in healthy individuals. However, differences according to histological subtype or treatment status are unclear. In addition, there has been less research on patients who subsequently develop breakthrough infections. We investigated the effects of the first COVID-19 booster vaccination for patients with B-NHL and the clinical features of breakthrough infections in the Omicron variant era. In this study, B-NHL was classified into two histological subtypes: aggressive lymphoma and indolent lymphoma. Next, patients were subdivided according to treatment with anticancer drugs at the start of the first vaccination. We also examined the clinical characteristics and outcomes of patients who had breakthrough infections after a booster vaccination. The booster effect of the COVID-19 mRNA vaccine in patients with B-NHL varied considerably depending on treatment status at the initial vaccination. In the patient group at more than 1 year after the last anticancer drug treatment, regardless of the histological subtype, the booster effect was comparable to that in the healthy control group. In contrast, the booster effect was significantly poorer in the other patient groups. However, of the 213 patients who received the booster vaccine, 22 patients (10.3%) were infected with COVID-19, and 18 patients (81.8%) had mild disease; these cases included the patients who remained seronegative. Thus, we believe that booster vaccinations may help in reducing the severity of Omicron variant COVID-19 infection in patients with B-NHL.https://www.mdpi.com/1999-4915/16/3/328B-cell non-Hodgkin’s lymphomaCOVID-19 mRNA vaccinebooster effectbreakthrough infectionOmicron variant |
| spellingShingle | Makoto Saito Akio Mori Takashi Ishio Mirei Kobayashi Shihori Tsukamoto Sayaka Kajikawa Emi Yokoyama Minoru Kanaya Koh Izumiyama Haruna Muraki Masanobu Morioka Takeshi Kondo Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin’s Lymphoma: A Single-Center Cohort Study Viruses B-cell non-Hodgkin’s lymphoma COVID-19 mRNA vaccine booster effect breakthrough infection Omicron variant |
| title | Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin’s Lymphoma: A Single-Center Cohort Study |
| title_full | Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin’s Lymphoma: A Single-Center Cohort Study |
| title_fullStr | Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin’s Lymphoma: A Single-Center Cohort Study |
| title_full_unstemmed | Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin’s Lymphoma: A Single-Center Cohort Study |
| title_short | Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin’s Lymphoma: A Single-Center Cohort Study |
| title_sort | initial efficacy of the covid 19 mrna vaccine booster and subsequent breakthrough omicron variant infection in patients with b cell non hodgkin s lymphoma a single center cohort study |
| topic | B-cell non-Hodgkin’s lymphoma COVID-19 mRNA vaccine booster effect breakthrough infection Omicron variant |
| url | https://www.mdpi.com/1999-4915/16/3/328 |
| work_keys_str_mv | AT makotosaito initialefficacyofthecovid19mrnavaccineboosterandsubsequentbreakthroughomicronvariantinfectioninpatientswithbcellnonhodgkinslymphomaasinglecentercohortstudy AT akiomori initialefficacyofthecovid19mrnavaccineboosterandsubsequentbreakthroughomicronvariantinfectioninpatientswithbcellnonhodgkinslymphomaasinglecentercohortstudy AT takashiishio initialefficacyofthecovid19mrnavaccineboosterandsubsequentbreakthroughomicronvariantinfectioninpatientswithbcellnonhodgkinslymphomaasinglecentercohortstudy AT mireikobayashi initialefficacyofthecovid19mrnavaccineboosterandsubsequentbreakthroughomicronvariantinfectioninpatientswithbcellnonhodgkinslymphomaasinglecentercohortstudy AT shihoritsukamoto initialefficacyofthecovid19mrnavaccineboosterandsubsequentbreakthroughomicronvariantinfectioninpatientswithbcellnonhodgkinslymphomaasinglecentercohortstudy AT sayakakajikawa initialefficacyofthecovid19mrnavaccineboosterandsubsequentbreakthroughomicronvariantinfectioninpatientswithbcellnonhodgkinslymphomaasinglecentercohortstudy AT emiyokoyama initialefficacyofthecovid19mrnavaccineboosterandsubsequentbreakthroughomicronvariantinfectioninpatientswithbcellnonhodgkinslymphomaasinglecentercohortstudy AT minorukanaya initialefficacyofthecovid19mrnavaccineboosterandsubsequentbreakthroughomicronvariantinfectioninpatientswithbcellnonhodgkinslymphomaasinglecentercohortstudy AT kohizumiyama initialefficacyofthecovid19mrnavaccineboosterandsubsequentbreakthroughomicronvariantinfectioninpatientswithbcellnonhodgkinslymphomaasinglecentercohortstudy AT harunamuraki initialefficacyofthecovid19mrnavaccineboosterandsubsequentbreakthroughomicronvariantinfectioninpatientswithbcellnonhodgkinslymphomaasinglecentercohortstudy AT masanobumorioka initialefficacyofthecovid19mrnavaccineboosterandsubsequentbreakthroughomicronvariantinfectioninpatientswithbcellnonhodgkinslymphomaasinglecentercohortstudy AT takeshikondo initialefficacyofthecovid19mrnavaccineboosterandsubsequentbreakthroughomicronvariantinfectioninpatientswithbcellnonhodgkinslymphomaasinglecentercohortstudy |